Owkin is an AI biotechnology company that aims to find personalized treatments for every patient by leveraging the power of artificial intelligence. Through their innovative approach, they identify new treatments, accelerate clinical trials, and develop diagnostic tools by integrating human and artificial intelligence. With a focus on protecting patient privacy and securing proprietary data, Owkin uses federated data access to unlock valuable insights from patient data. Founded in 2016 by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in machine learning in biology, Owkin has raised over $300 million in funding and has become a unicorn in the industry. Their team of experts collaborates with leading biopharma companies and academic researchers to address the challenges in biopharma research and improve the understanding of disease mechanics. With offices in multiple locations including Paris, New York, and London, Owkin is at the forefront of revolutionizing precision medicine.Generated from the website

Kennys Castaways

New York Bridal Hair

Carroll Place

A Night of Burlesque